Loading clinical trials...
Loading clinical trials...
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After Induction Therapy of Rituximab Combined With Bendamustine (BR) or Cyclophosphamide, Vincristine, Doxorubicin, Prednisone (RCHOP) or Lenalidomide (R2): a Multicenter Clinical Study
Conditions
Interventions
BR for 6 cycles +R for 8 cycles
RCHOP for 6 cycles +R for 8 cycles
+1 more
Locations
1
China
Ruijin Hospital
Shanghai, China
Start Date
March 1, 2021
Primary Completion Date
March 1, 2023
Completion Date
March 1, 2024
Last Updated
April 13, 2021
NCT06337318
NCT05006716
NCT06026319
NCT07128641
NCT06510361
NCT01804686
Lead Sponsor
Ruijin Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions